Hans Biomed Corp

Hans Biomed Corp operates with a capital structure that includes a debt-to-equity ratio of 1.28, indicating a moderate reliance on debt financing. The company's liquidity position is characterized by a current ratio of 0.69, suggesting potential short-term liquidity constraints. The company's cash and equivalents amount to 6,667,447,000 KRW, which is significantly lower than its long-term debt of 43,306,596,390 KRW, resulting in a negative net cash position. Profitability metrics for Hans Biomed Corp are underperforming relative to industry norms. The company reported a net loss of 31,341,350,200 KRW and an operating loss of 25,890,557,570 KRW, with a return on equity of -0.93 and a return on assets of -0.25. These figures indicate a significant deviation from the typical performance of firms in the Medical Equipment, Supplies & Distribution industry. The company's revenue is primarily derived from its core medical devices business, with a focus on skin and bone grafts, facial tissue fixation sutures, and silicone products. There is no indication of geographic diversification in the provided data, suggesting a concentration of revenue within its domestic market. Hans Biomed Corp's growth trajectory is currently constrained by its financial performance. The company's free cash flow is negative at -29,177,299,300 KRW, and capital expenditures are at -1,757,565,930 KRW, indicating a lack of investment in growth initiatives. Analysts have provided a mean price target of 64,000 KRW, with a strong buy recommendation, but the company's current financial position may limit its ability to capitalize on growth opportunities. The risk assessment for Hans Biomed Corp highlights medium liquidity risk and low dilution risk. The company's negative net cash position after subtracting total debt is a key flag, indicating potential challenges in meeting short-term obligations. The dilution risk is assessed as low, with no immediate pressure for additional equity issuance. Recent events and filings for Hans Biomed Corp do not provide specific details on new product launches, regulatory changes, or strategic partnerships. The company's financial performance and liquidity position are the primary factors influencing its current market perception.